Zacks Research Lifts Earnings Estimates for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Zacks Research upped their Q2 2026 earnings estimates for Gilead Sciences in a note issued to investors on Friday, April 4th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings of $1.84 per share for the quarter, up from their prior forecast of $1.83. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences' Q4 2026 earnings at $2.29 EPS, FY2026 earnings at $8.02 EPS, Q1 2027 earnings at $1.88 EPS and FY2027 earnings at $8.62 EPS.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%.

Other equities research analysts have also recently issued research reports about the stock. BMO Capital Markets increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Bank of America lifted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Royal Bank of Canada increased their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, Piper Sandler boosted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Remove Ads

Gilead Sciences Price Performance

Gilead Sciences stock traded down $3.85 during mid-day trading on Monday, hitting $101.40. 14,191,080 shares of the company were exchanged, compared to its average volume of 7,483,490. The company has a market capitalization of $126.26 billion, a PE ratio of 274.05, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The business has a fifty day moving average of $108.23 and a 200 day moving average of $96.64. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. McAdam LLC lifted its position in shares of Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock worth $2,344,000 after purchasing an additional 3,627 shares in the last quarter. Capital Investment Advisors LLC lifted its position in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after buying an additional 9,791 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in shares of Gilead Sciences by 3.9% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock worth $13,132,000 after buying an additional 5,382 shares during the last quarter. Global Financial Private Client LLC grew its holdings in shares of Gilead Sciences by 1,222.0% in the 4th quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company's stock valued at $561,000 after acquiring an additional 5,609 shares in the last quarter. Finally, Exome Asset Management LLC bought a new stake in Gilead Sciences during the third quarter worth about $4,192,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.12%. The ex-dividend date of this dividend was Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.